Michaela B Kirschner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1170412/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Haemolysis during Sample Preparation Alters microRNA Content of Plasma. PLoS ONE, 2011, 6, e24145.	1.1	442
2	Circulating microRNAs: Association with disease and potential use as biomarkers. Critical Reviews in Oncology/Hematology, 2011, 80, 193-208.	2.0	421
3	The Impact of Hemolysis on Cell-Free microRNA Biomarkers. Frontiers in Genetics, 2013, 4, 94.	1.1	266
4	Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Annals of Oncology, 2013, 24, 3128-3135.	0.6	221
5	Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant PleuralÂMesothelioma. Journal of Thoracic Oncology, 2017, 12, 1421-1433.	0.5	121
6	Increased Circulating miR-625-3p: A Potential Biomarker for Patients With Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2012, 7, 1184-1191.	0.5	115
7	Combined Genetic and Genealogic Studies Uncover a Large BAP1 Cancer Syndrome Kindred Tracing Back Nine Generations to a Common Ancestor from the 1700s. PLoS Genetics, 2015, 11, e1005633.	1.5	76
8	miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma. Oncotarget, 2015, 6, 23480-23495.	0.8	76
9	Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis. British Journal of Cancer, 2015, 113, 963-969.	2.9	68
10	MiRâ€Score: A novel 6â€microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma. Molecular Oncology, 2015, 9, 715-726.	2.1	67
11	Cell-free microRNAs: potential biomarkers in need of standardized reporting. Frontiers in Genetics, 2013, 4, 56.	1.1	60
12	A data-driven, knowledge-based approach to biomarker discovery: application to circulating microRNA markers of colorectal cancer prognosis. Npj Systems Biology and Applications, 2018, 4, 20.	1.4	47
13	KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma. Molecular Cancer, 2016, 15, 44.	7.9	46
14	An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. British Journal of Cancer, 2014, 110, 510-519.	2.9	45
15	Loss of miR-223 and JNK Signaling Contribute to Elevated Stathmin in Malignant Pleural Mesothelioma. Molecular Cancer Research, 2015, 13, 1106-1118.	1.5	44
16	Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2018, 13, 258-272.	0.5	40
17	Long Non Coding RNAs (IncRNAs) Are Dysregulated in Malignant Pleural Mesothelioma (MPM). PLoS ONE, 2013, 8, e70940.	1.1	33
18	FGF2 and EGF induce epithelial–mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal. Carcinogenesis, 2018, 39, 534-545.	1.3	32

Michaela B Kirschner

#	Article	IF	CITATIONS
19	ZIC1 Is Silenced and Has Tumor Suppressor Function in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2013, 8, 1317-1328.	0.5	30
20	Tumor Immune Microenvironment and Genetic Alterations in Mesothelioma. Frontiers in Oncology, 2021, 11, 660039.	1.3	28
21	A link between the fibroblast growth factor axis and the miRâ€16 family reveals potential new treatment combinations in mesothelioma. Molecular Oncology, 2018, 12, 58-73.	2.1	27
22	Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma – A multi-institutional study. European Journal of Cancer, 2016, 63, 64-73.	1.3	21
23	Alterations in <i>BAP1</i> Are Associated with Cisplatin Resistance through Inhibition of Apoptosis in Malignant Pleural Mesothelioma. Clinical Cancer Research, 2021, 27, 2277-2291.	3.2	21
24	A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma. British Journal of Cancer, 2016, 114, 524-531.	2.9	20
25	Molecular Research in Chronic Thromboembolic Pulmonary Hypertension. International Journal of Molecular Sciences, 2019, 20, 784.	1.8	19
26	Abstract 3976: Targeted delivery of a synthetic microRNA-based mimic as an approach to cancer therapy. Cancer Research, 2015, 75, 3976-3976.	0.4	15
27	Transcriptional suppression of the miR-15/16 family by c-Myc in malignant pleural mesothelioma. Oncotarget, 2019, 10, 4125-4138.	0.8	13
28	Posttranscriptional Regulation Controls Calretinin Expression in Malignant Pleural Mesothelioma. Frontiers in Genetics, 2017, 8, 70.	1.1	12
29	miR-625-3p and IncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and Surgery. Non-coding RNA, 2019, 5, 41.	1.3	11
30	When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?. Frontiers in Endocrinology, 2019, 10, 89.	1.5	10
31	MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients. Genomics Data, 2016, 9, 44-49.	1.3	5
32	Importance of Cullin4 Ubiquitin Ligase in Malignant Pleural Mesothelioma. Cancers, 2020, 12, 3460.	1.7	5
33	Primary Lung Cancer Organoids for Personalized Medicine—Are They Ready for Clinical Use?. Cancers, 2021, 13, 4832.	1.7	4
34	Surgical management of lung cancer during the COVID-19 pandemic – a narrative review and single-centre report. Swiss Medical Weekly, 2022, 152, w30109.	0.8	3
35	OA02.01 The microRNA-15/16 Family Regulates Tumor Cell Growth via Fibroblast Growth Factor Signals in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2017, 12, S246.	0.5	2
36	OA22.06 Refinement of the Prognostic miR-Score for Use in Diagnostic Specimens from Chemo-NaÃ⁻ve Malignant Pleural Mesothelioma Patients. Journal of Thoracic Oncology, 2017, 12, S332.	0.5	2

Michaela B Kirschner

#	Article	IF	CITATIONS
37	OA02.05 Expression of miR-223 in Mesothelioma Xenografts Originates from Stromal Cells in the Tumor Microenvironment. Journal of Thoracic Oncology, 2017, 12, S248.	0.5	1
38	Does miR-1 Play a Role in Malignant Pleural Mesothelioma Development and Progression?. Chest, 2013, 144, 1971.	0.4	0
39	54: An evaluation of lysine demethylase family members in malignant pleural mesothelioma. Lung Cancer, 2015, 87, S21-S22.	0.9	0
40	P3.03-001 Targeting Cullin Ubiquitin Ligase Leads to Growths Arrest in Malignant Pleural Mesothelioma Cells. Journal of Thoracic Oncology, 2017, 12, S1343.	0.5	0
41	P3.03-008 Hypoxia-Induced Changes in microRNA Levels Contribute to Drug Resistance inÂa 3D Model of Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2017, 12, S1348.	0.5	0
42	P3.03-044 Is Toxicity Increased by Adding Intraoperative Chemotherapy to Preoperative Induction Chemotherapy for Mesothelioma Patients?. Journal of Thoracic Oncology, 2017, 12, S1372-S1373.	0.5	0
43	OA02.03 Circulating Fibroblast Growth Factor 18 is Elevated in Malignant Pleural Mesothelioma Patients - A Multi-Institutional Study. Journal of Thoracic Oncology, 2017, 12, S247-S248.	0.5	0
44	Abstract LB-352: Functional significance of Zic1 and hsa-miR-23a over-expression in malignant mesothelioma. , 2011, , .		0
45	A novel microRNA-based treatment approach for malignant pleural mesothelioma Journal of Clinical Oncology, 2013, 31, 7586-7586.	0.8	0
46	Prognostic significance of circulating secreted protein acidic and rich in cysteine (SPARC) in malignant pleural mesothelioma (MPM) Journal of Clinical Oncology, 2014, 32, 7580-7580.	0.8	0
47	Levels of plasma fibulin-3 and accuracy of identifying patients with malignant pleural mesothelioma Journal of Clinical Oncology, 2014, 32, e18543-e18543.	0.8	0
48	MicroRNA expression analysis in Chronic Thromboembolic Pulmonary Hypertension using pulmonary endarterectomy derived samples. , 2020, , .		0